Peptides Similar to Melanotan-2

Peptides Related to Melanotan-2#

Several peptides share functional overlap with Melanotan-2 in tissue repair and healing research. Below is a detailed comparison of their mechanisms, efficacy, and potential for combination use.

Thymosin Beta-4 (TB-500)#

We compared the research efficacy of Melanotan‑2/PT‑141/bremelanotide, Thymosin beta‑4 (including TB‑500/RGN‑259), and GHK‑Cu across randomized clinical evidence, endpoints, and safety, and noted head‑to‑head data where present.

Melanotan‑2/PT‑141/bremelanotide (sexual function)

• Evidence base and efficacy: For female HSDD, two 24‑week, phase‑3 randomized, double‑blind, placebo‑controlled trials (RECONNECT) met both prespecified coprimary endpoints: improvements in FSFI‑Desire and reductions in FSDS‑DAO vs placebo; integrated FSFI‑D effect ~+0.35 with higher responder rates vs placebo (≈58% vs ≈36%). A prespecified satisfying sexual events endpoint showed inconsistent results, with supportive post hoc findings. In men with ED, smaller randomized/crossover studies showed increased erectile rigidity duration and benefits in sildenafil non‑responders, but development was limited by blood‑pressure effects in earlier intranasal programs (summarized mechanistically and clinically). (pqac‑00000002, pqac‑00000000)
• Safety: Nausea (~40%), flushing (~20%), headache (~11%) were common; transient BP increases were observed; discontinuations occurred in a minority. (pqac‑00000002, pqac‑00000000)
• Regulatory status: Bremelanotide (Vyleesi) is FDA‑approved for premenopausal HSDD on the basis of the phase‑3 program. (pqac‑00000002)

Thymosin beta‑4/TB‑500/RGN‑259 (tissue repair/ocular surface)

• Evidence base and efficacy: In a randomized, double‑masked, placebo‑controlled Phase II dry‑eye trial using the CAE model (n=72; 28 days), coprimary endpoints—ocular discomfort and inferior corneal staining at 24‑hour post‑CAE—were not met. However, central and superior corneal staining improved vs placebo (e.g., central staining at 24‑hour post‑CAE: LS mean difference −0.52; P=0.0075) and CAE‑associated discomfort increased less with Tβ4 (≈27% reduction vs placebo; P=0.0244). Safety was favorable with low TEAE rates. (pqac‑00000021, pqac‑00000022, pqac‑00000026)
• Chronic cutaneous ulcers: Randomized dose‑escalation trials (pressure/venous stasis) reported signals, including faster healing at 0.02–0.03% (e.g., wound size reduction 57% vs 30% at day 14; P=0.0149), though detailed primary endpoint hierarchies and blinding specifics vary across reports. (pqac‑00000004, pqac‑00000003)
• Overall: Human randomized data show safety and secondary‑endpoint improvements in dry‑eye and signals for accelerated dermal healing, but pivotal coprimary endpoints in the CAE dry‑eye trial were not met. (pqac‑00000021, pqac‑00000022, pqac‑00000004)

GHK‑Cu (topical anti‑aging/wound)

• Evidence base and efficacy: A randomized, double‑blind, split‑face 8‑week cosmetic trial in 40 women compared nano‑carrier GHK‑Cu (NRFS) to Matrixyl 3000 (a lipophilic GHK derivative) and vehicle, with 3D profilometry (PRIMOS) as objective endpoints. NRFS reduced wrinkle volume by 55.8% vs vehicle (p<0.001) and 31.6% vs Matrixyl (p=0.004), and reduced wrinkle depth by 32.8% vs vehicle (p=0.012). In vitro components showed increased collagen and elastin production and modulation of MMP/TIMP expression. The topical formulation was generally well tolerated (one minor local reaction). Systematic reviews note that many peptide studies are multi‑ingredient and small, which can confound attribution; however, this split‑face RCT used objective measures and blinded assessment. (pqac‑00000016, pqac‑00000015, pqac‑00000001, pqac‑00000014)

Head‑to‑head data

• No randomized head‑to‑head comparisons were identified between the peptide classes (Melanotan‑2/PT‑141/bremelanotide vs Tβ4/TB‑500 vs GHK‑Cu). One intra‑class split‑face RCT compared nano‑carrier GHK‑Cu to Matrixyl 3000 and vehicle and favored nano‑GHK‑Cu. (pqac‑00000016)

Comparative research efficacy summary

• Strength of clinical evidence: Bremelanotide has the most robust evidence with phase‑3 RCTs meeting prespecified coprimary endpoints in HSDD and resulting in FDA approval; ED data exist but are smaller and constrained by safety considerations in earlier delivery modes. (pqac‑00000002, pqac‑00000000)
• Thymosin beta‑4/TB‑500 shows human randomized signals—particularly secondary endpoints in dry‑eye and healing signals in ulcer studies—but the key CAE phase‑II coprimary endpoints were not met; overall strength is moderate and still investigational. (pqac‑00000021, pqac‑00000022, pqac‑00000004)
• GHK‑Cu demonstrates cosmetic‑level randomized split‑face efficacy with objective wrinkle metrics over 8 weeks and supportive mechanistic data, but the evidence is limited to small cosmetic trials, not drug‑level pivotal studies. (pqac‑00000016, pqac‑00000015)

Implications for selection

• For centrally mediated sexual function indications, bremelanotide has registrational evidence and defined safety; MT‑II/PT‑141 ED use remains investigational and constrained by tolerability in some regimens. (pqac‑00000002, pqac‑00000000)
• For tissue repair/ocular surface, Tβ4/RGN‑259 shows promise but requires confirmatory trials with coprimary endpoint success; limited dermal ulcer data suggest potential benefit at specific topical doses. (pqac‑00000021, pqac‑00000004)
• For dermatologic cosmeceutical outcomes, GHK‑Cu has randomized split‑face evidence with sizable effect sizes on wrinkle metrics over short durations, supporting cosmetic use while acknowledging limited generalizability and need for larger independent trials. (pqac‑00000016, pqac‑00000014)

LL-37 (Cathelicidin)#

What is missing. No direct studies were identified that test MT‑2 (or PT‑141) co‑administered with BPC‑157, thymosin‑β4 (TB‑500), GHK‑Cu, LL‑37, or growth factors for wound healing or tissue regeneration. Likewise, we found no registered clinical trials testing such combinations in healing indications (search negative).

Implications for combinations with “healing peptides.”

• Infection‑prone wounds: Based on α‑MSH–antibiotic synergy, pairing a melanocortin agonist with topical/systemic antibiotics could be advantageous against MRSA in infected wounds; translation requires in vivo validation.
• Epithelial closure and barrier repair: Given the NO‑dependence of KPV’s wound actions and barrier‑protective effects of melanocortins, combinations with NO‑donor strategies or peptides that strengthen tight junctions may be complementary; this remains hypothesis‑generating.
• Fibrosis/scar modulation: The α‑MSH monotherapy data showing improved remodeling suggest potential complementarity with agents that promote re‑epithelialization (e.g., EGF) or angiogenesis (e.g., VEGF) to cover multiple healing phases; explicit combination data are currently lacking.

Limitations. The strongest combination evidence pertains to antimicrobial synergy in vitro and to complementary effects in erectile dysfunction, not to MT‑2 plus other healing peptides in wound models. Dedicated preclinical and clinical studies are needed to substantiate synergy or additivity for healing outcomes.

Embedded artifact summarizing the key combination evidence and gaps:

KPV#

Evidence details.

• Antimicrobial synergy (infection control context): α‑MSH combined with conventional antibiotics produced synergistic or enhanced bactericidal effects against a clinical MRSA isolate in vitro. Adding α‑MSH reduced minimum bactericidal concentrations by ≥64‑fold (gentamicin), 8‑fold (ciprofloxacin), and 4‑fold (tetracycline), with additive/enhanced killing noted with rifampicin and oxacillin; mechanistic assays support complementary actions (membrane perturbation and inhibition of DNA/protein synthesis).
• Clinical co‑administration complementarity (non‑healing indication): Reviews and clinical reports note enhanced erectile responses when the melanocortin agonist bremelanotide (PT‑141) is co‑administered with PDE5 inhibitors, illustrating that melanocortin agonists can act complementarily with other agents in humans, albeit outside wound‑healing contexts.
• Mechanistic complementarity for healing: A focused review concludes melanocortin peptides (α‑MSH, NDP‑α‑MSH, KPV, KdPT) modulate early inflammation, cytoprotection, oxidative stress, and collagen turnover across healing phases, providing a rationale for combining with agents that support nitric oxide signaling or epithelial barrier function; for example, KPV‑driven corneal epithelial closure depends on NO (blocked by NOS inhibition), and KdPT preserves tight junctions under high‑glucose stress. These findings are supportive of complementary combinations, but the review notes the lack of explicit combination trials with MT‑2.
• Contextual monotherapy wound‑healing data: In mice, a single intraperitoneal dose of α‑MSH given before wounding reduced early leukocyte infiltration, improved extracellular matrix remodeling (reticular collagen architecture), increased collagen III at 40 days, and reduced scarring by 40–60 days—effects that could pair well with agents targeting epithelial migration or angiogenesis in a future combination design.

Mechanism Comparison#

Which peptides share overlapping mechanisms with MT‑2?

• Strong overlap: α‑MSH and afamelanotide (MT‑1) via broad MCR agonism (not MC2R) and canonical Gs→cAMP→PKA signaling, particularly at MC1R (pigmentary/anti‑inflammatory) and neural MC3R/MC4R where relevant (pqac‑00000003, pqac‑00000004, pqac‑00000001, pqac‑00000002).
• Substantial overlap: Bremelanotide (PT‑141), which is derived from MT‑2 and shares MC1R activity while adding emphasis on MC4R‑mediated central effects; signaling at MC4R is also Gs→cAMP→PKA (pqac‑00000001, pqac‑00000004).
• Partial/selective overlap: Setmelanotide overlaps at MC4R Gs→cAMP but differs by MC4R selectivity and evidence of signaling bias relative to endogenous/synthetic ligands (pqac‑00000007, pqac‑00000004).
• Limited overlap: ACTH is mechanistically distinct by primary MC2R specificity; outside MC2R, any overlap with MT‑2 at other MCRs is secondary (pqac‑00000004, pqac‑00000005).

Conclusion MT‑2 functions as a nonselective melanocortin agonist (excluding MC2R) that primarily engages Gs→cAMP→PKA, with context‑dependent ERK/MAPK. Most overlap with MT‑2 is seen for α‑MSH and afamelanotide (broad MCR agonism including MC1R) and for bremelanotide (shared MC1R plus MC4R‑mediated central actions). Setmelanotide overlaps at MC4R Gs→cAMP but differs in selectivity and bias; ACTH is largely distinct due to MC2R specificity (pqac‑00000002, pqac‑00000003, pqac‑00000005, pqac‑00000004, pqac‑00000001, pqac‑00000007).

Evidence Gaps#

Direct head-to-head comparison studies between Melanotan-2 and related peptides are limited. Most comparisons are based on separate studies with different methodologies, making direct efficacy comparisons difficult.

Related Reading#

• Melanotan-2 overview and research guide
• Melanotan-2 research evidence
• Melanotan-2 dosing protocols